TrialBritish journal of clinical pharmacology2020

Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study.

Jaeseong Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.